Blocking CB1 receptors alongside activating NOP receptors worsened colitis in mice
Combining a CB1 receptor blocker with a NOP receptor activator unexpectedly worsened intestinal inflammation in a mouse colitis model, revealing a complex interaction between the endocannabinoid and nociceptin systems.
Quick Facts
What This Study Found
Mice with DSS-induced colitis treated with both AM6545 and SCH221510 showed significantly worse macroscopic disease scores and altered signaling compared to SCH221510 alone.
Key Numbers
Significant increase in macroscopic colitis score with AM6545+SCH221510 vs SCH221510 alone. Lower ERK1/2 levels. Higher p-AKT and beta-arrestin in the combination group.
How They Did This
Mouse colitis model using 3% DSS, with selective ligands for CB1 (antagonist AM6545), CB2 (antagonist AM630), and NOP receptor (agonist SCH221510). Assessed macroscopic/microscopic scores, western blots, qPCR, and LC-MS.
Why This Research Matters
Both the endocannabinoid system and NOP receptors are being explored as IBD targets. This study reveals that their interaction can worsen rather than improve outcomes.
The Bigger Picture
Drug development for IBD increasingly targets the endocannabinoid system. This cautionary finding shows receptor interactions must be carefully studied before combination therapies.
What This Study Doesn't Tell Us
Single mouse colitis model (DSS). Only acute colitis studied. Mechanism not fully elucidated.
Questions This Raises
- ?Would CB2 antagonism produce similar adverse interactions?
- ?Is this interaction relevant to humans with IBD?
Trust & Context
- Key Stat:
- Combination treatment worsened colitis beyond either agent alone
- Evidence Grade:
- Well-designed animal study with multiple molecular endpoints, but findings need validation across other IBD models.
- Study Age:
- Published in 2025.
- Original Title:
- Combined CB1 antagonist AM6545 and NOP agonist SCH221510 worsen DSS-induced colitis in mice.
- Published In:
- Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 34(12), 2153-2162 (2025)
- Authors:
- Fabisiak, Adam(2), Wołyniak, Maria R, Piscitelli, Fabiana(5), Verde, Roberta, Marzo, Vincenzo Di, Zielińska, Marta, Machelak, Weronika, Małecka-Wojciesko, Ewa
- Database ID:
- RTHC-06428
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can targeting the endocannabinoid system help with colitis?
While individual targets show promise, this study found combining a CB1 blocker with a NOP receptor activator actually worsened colitis.
What does this mean for drug development?
It suggests that combination therapies targeting the endocannabinoid and nociceptin systems need careful testing, as they can interact negatively.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06428APA
Fabisiak, Adam; Wołyniak, Maria R; Piscitelli, Fabiana; Verde, Roberta; Marzo, Vincenzo Di; Zielińska, Marta; Machelak, Weronika; Małecka-Wojciesko, Ewa. (2025). Combined CB1 antagonist AM6545 and NOP agonist SCH221510 worsen DSS-induced colitis in mice.. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 34(12), 2153-2162. https://doi.org/10.17219/acem/203426
MLA
Fabisiak, Adam, et al. "Combined CB1 antagonist AM6545 and NOP agonist SCH221510 worsen DSS-induced colitis in mice.." Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2025. https://doi.org/10.17219/acem/203426
RethinkTHC
RethinkTHC Research Database. "Combined CB1 antagonist AM6545 and NOP agonist SCH221510 wor..." RTHC-06428. Retrieved from https://rethinkthc.com/research/fabisiak-2025-combined-cb1-antagonist-am6545
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.